BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31422225)

  • 1. Galloyl esters of trans-stilbenes are inhibitors of FASN with anticancer activity on non-small cell lung cancer cells.
    Tan YJ; Ali A; Tee SY; Teo JT; Xi Y; Go ML; Lam Y
    Eur J Med Chem; 2019 Nov; 182():111597. PubMed ID: 31422225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway.
    Chang L; Fang S; Chen Y; Yang Z; Yuan Y; Zhang J; Ye L; Gu W
    Lipids Health Dis; 2019 May; 18(1):118. PubMed ID: 31122252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkyl esters of gallic acid as anticancer agents: a review.
    Locatelli C; Filippin-Monteiro FB; Creczynski-Pasa TB
    Eur J Med Chem; 2013 Feb; 60():233-9. PubMed ID: 23291333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
    Mullen GE; Yet L
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review on target domains and natural compound-based inhibitors of fatty acid synthase for anticancer drug discovery.
    Pulla LSS; Begum Ahil S
    Chem Biol Drug Des; 2021 Nov; 98(5):869-884. PubMed ID: 34459114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.
    Lu T; Schubert C; Cummings MD; Bignan G; Connolly PJ; Smans K; Ludovici D; Parker MH; Meyer C; Rocaboy C; Alexander R; Grasberger B; De Breucker S; Esser N; Fraiponts E; Gilissen R; Janssens B; Peeters D; Van Nuffel L; Vermeulen P; Bischoff J; Meerpoel L
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2159-2164. PubMed ID: 29779975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VDAC1 Mediated Anticancer Activity of Gallic Acid in Human Lung Adenocarcinoma A549 Cells.
    Maimaiti A; Aili A; Kuerban H; Li X
    Anticancer Agents Med Chem; 2018; 18(2):255-262. PubMed ID: 28901260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
    Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
    J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer.
    Grunt TW; Slany A; Semkova M; Colomer R; López-Rodríguez ML; Wuczkowski M; Wagner R; Gerner C; Stübiger G
    Sci Rep; 2020 Sep; 10(1):14877. PubMed ID: 32913236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.
    Al-Sanea MM; Al-Ansary GH; Elsayed ZM; Maklad RM; Elkaeed EB; Abdelgawad MA; Bukhari SNA; Abdel-Aziz MM; Suliman H; Eldehna WM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):987-999. PubMed ID: 33985397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
    Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
    Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
    Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
    Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
    Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones.
    Cagir A; Odaci B; Varol M; Akcok I; Okur O; Koparal AT
    Anticancer Agents Med Chem; 2018 Feb; 17(14):1915-1923. PubMed ID: 28554313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions.
    Zhang Y; Meng X; Tang H; Cheng M; Yang F; Xu W
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):344-353. PubMed ID: 31851852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Natural-Based Antitumor Compound T21 Decreases Survivin Levels through Potent STAT3 Inhibition in Lung Cancer Models.
    Martínez-García D; Pérez-Hernández M; Korrodi-Gregório L; Quesada R; Ramos R; Baixeras N; Pérez-Tomás R; Soto-Cerrato V
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31412593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
    Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
    Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent AI-Modeling of the anticancer efficacy of synthesized gallic acid analogues.
    Sherin L; Sohail A; Shujaat S
    Comput Biol Chem; 2019 Apr; 79():137-146. PubMed ID: 30818108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.